PT - JOURNAL ARTICLE AU - Jung, Junghyun AU - Lu, Zeyun AU - de Smith, Adam AU - Mancuso, Nicholas TI - Novel insight into the etiology of ischemic stroke gained by integrative transcriptome-wide association study AID - 10.1101/2023.03.30.23287918 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.30.23287918 4099 - http://medrxiv.org/content/early/2023/03/31/2023.03.30.23287918.short 4100 - http://medrxiv.org/content/early/2023/03/31/2023.03.30.23287918.full AB - Stroke, characterized by sudden neurological deficits, is the second leading cause of death worldwide. Although genome-wide association studies (GWAS) have successfully identified many genomic regions associated with ischemic stroke (IS), the genes underlying risk and their regulatory mechanisms remain elusive. Here, we integrate a large-scale GWAS (N=1,296,908) for IS together with mRNA, splicing, enhancer RNA (eRNA) and protein expression data (N=11,588) from 50 tissues. We identify 136 genes/eRNA/proteins associated with IS risk across 54 independent genomic regions and find IS risk is most enriched for eQTLs in arterial and brain-related tissues. Focusing on IS-relevant tissues, we prioritize 9 genes/proteins using probabilistic fine-mapping TWAS analyses. In addition, we discover that blood cell traits, particularly reticulocyte cells, have shared genetic contributions with IS using TWAS-based pheWAS and genetic correlation analysis. Lastly, we integrate our findings with a large-scale pharmacological database and identify a secondary bile acid, deoxycholic acid, as a potential therapeutic component. Our work highlights IS risk genes/splicing-sites/enhancer activity/proteins with their phenotypic consequences using relevant tissues as well as identify potential therapeutic candidates for IS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in part by the National Institutes of Health (NIH) under awards R01HG012133 and R01GM140287.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:- Iscemic stroke summary statistics (GIGASTROKE): https://www.ebi.ac.uk/gwas/studies/GCST90104540 - FUSION: https://github.com/gusevlab/fusion_twas - GWAS summary statistics (UK Biobank): http://www.nealelab.is/uk-biobankI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.